Study reveals disease mechanisms that may drive biliary atresia
A new preclinical study has found that a combination of viral and bacterial insults may be a key disease mechanism underlying biliary atresia. Specifically,…
News
World Hepatitis Day is aiming for a world without viral hepatitis
World Hepatitis Day arrives Monday and advocates are gearing up to break down barriers that stand in the way of a world free from…
PPAR agonists effective in UDCA-resistant primary biliary cholangitis
A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver function and ease itching in…
Bylvay eases itching in episodic PFIC1, boosting daily life: Study
Bylvay (odevixibat) eased pruritus — itching — during episodes of progressive familial intrahepatic cholestasis (PFIC) type 1 caused by mutations in both copies of…
Madrigal wins US patent for Rezdiffra dosing regimen in MASH
The U.S. Patent and Trademark Office (USPTO) is granting a patent for Rezdiffra (resmetirom) — Madrigal Pharmaceuticals’ approved therapy for metabolic dysfunction-associated steatohepatitis (MASH),…
Scientists ID ways to aid Alagille syndrome diagnosis in infants
In infants younger than 3 months, identifying heart problems and distinctive facial features, as well as blood markers and certain liver tissue abnormalities, may aid…
Hepatitis C treatment rates low among some at-risk US populations
Access to hepatitis C treatment and care remains low among children and recently pregnant women in the U.S., according to data from two recently…
Umecrine raises $2.5M to advance trial testing golexanolone for PBC
Umecrine Cognition has raised around $2.5 million to support an ongoing Phase 1b/2a clinical trial testing its investigational therapy golexanolone for cognitive problems and…
Severe ICP raises risk in twin pregnancy, study finds
Severe intrahepatic cholestasis of pregnancy (ICP) significantly raises the risks of adverse outcomes in twin pregnancies, according to a single-center, retrospective study conducted in…
Preclinical safety data support ETX-312 for MASH human trials
E-therapeutics announced positive preclinical toxicology data on ETX-312, its therapy for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver…
Recent Posts
- Drug combo shrinks liver fat in rats and zebrafish: Study
- Know your risks – and options – this National Liver Awareness Month
- Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment
- PBC worst for life quality among autoimmune liver diseases: Study
- Changes big and small can benefit those of us with MASH